Journal Article

<i>Mycobacterium kansasii</i> Disease in Patients Infected with Human Immunodeficiency Virus

Rafael E. Campo and Carlos E. Campo

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 24, issue 6, pages 1233-1238
Published in print June 1997 | ISSN: 1058-4838
Published online June 1997 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/513666
Mycobacterium kansasii Disease in Patients Infected with Human Immunodeficiency Virus

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm3), when most patients had already developed AIDS; 91.3% of the patients had pulmonary involvement, and 21.7% had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for ∼4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival ±SE, 73.7 weeks ± 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival ±SE, 57.3 ± 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival ± SE, 14.1 ± 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.